Curcumin Alleviates Epidermal Psoriasis-Like Dermatitis and IL-6/STAT3 Pathway of Mice

References

• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nature Rev. 2016;2:16082. doi:10.1038/nrdp.2016.82
   Web of Science ®Google Scholar
• Loft ND, Andersen CH, Halling-Overgaard AS, Thyssen JP, Skov L, Egeberg A. Validation of psoriasis diagnoses in the Danish national patient register. Acta Derm Venereol. 2019;99(11):1037–1038. doi:10.2340/00015555-3278
   PubMed Web of Science ®Google Scholar
• Shrivastava VK, Londhe ND, Sonawane RS, Suri JS. First review on psoriasis severity risk stratification: an engineering perspective. Comput Biol Med. 2015;63:52–63. doi:10.1016/j.compbiomed.2015.05.005
   PubMed Web of Science ®Google Scholar
• Oji V, Luger TA. The skin in psoriasis: assessment and challenges. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S14–S19.
   PubMed Web of Science ®Google Scholar
• Yi F, Zheng X, Fang F, Zhang J, Zhou B, Chen X. ALA-PDT alleviates the psoriasis by inhibiting JAK signalling pathway. Exp Dermatol. 2019;28(11):1227–1236. doi:10.1111/exd.14017
   PubMed Web of Science ®Google Scholar
• Miao X, Xiang Y, Mao W, Chen Y, Li Q, Fan B. TRIM27 promotes IL-6-induced proliferation and inflammation factor production by activating STAT3 signaling in HaCaT cells. Am J Physiol Cell Physiol. 2020;318(2):C272–C281. doi:10.1152/ajpcell.00314.2019
   PubMed Web of Science ®Google Scholar
• Hou M, Xing H, Cai Y, et al. Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis. Eur J Dermatol. 2019;29(3):302–314. doi:10.1684/ejd.2019.3553
   PubMed Web of Science ®Google Scholar
• Nogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context. 2019;8:212594. doi:10.7573/dic.212594
   PubMedGoogle Scholar
• Mikhaylov D, Hashim PW, Nektalova T, Goldenberg G. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits. J Clin Aesthet Dermatol. 2019;12(6):46–54.
   PubMedGoogle Scholar
• Nagata M, Kamata M, Ohtsuki M, Sato S, Tada Y. Scalp psoriasis in a haemodialysis patient successfully treated with a half-dose of apremilast. Eur J Dermatol. 2019;29(3):341–342. doi:10.1684/ejd.2019.3588
   PubMed Web of Science ®Google Scholar
• Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. J Med Chem. 2017;60(5):1620–1637. doi:10.1021/acs.jmedchem.6b00975
   PubMed Web of Science ®Google Scholar
• Lestari ML, Indrayanto G. Curcumin. Profiles Drug Subst Excip Relat Methodol. 2014;39:113–204.
   PubMedGoogle Scholar
• Tsuda T. Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives. Food Funct. 2018;9(2):705–714. doi:10.1039/C7FO01242J
   PubMed Web of Science ®Google Scholar
• Bachmeier BE, Melchart D. Therapeutic effects of curcumin-from traditional past to present and future clinical applications. Int J Mol Sci. 2019;20(15):3757. doi:10.3390/ijms20153757
   PubMed Web of Science ®Google Scholar
• Gong Z, Zhou J, Li H, et al. Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Mol Nutr Food Res. 2015;59(11):2132–2142. doi:10.1002/mnfr.201500316
   PubMed Web of Science ®Google Scholar
• Baek JO, Byamba D, Wu WH, Kim TG, Lee MG. Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress. Arch Dermatol Res. 2012;304(9):699–706. doi:10.1007/s00403-012-1272-y
   PubMed Web of Science ®Google Scholar
• Wu JK, Siller G, Strutton G. Psoriasis induced by topical imiquimod. Australas J Dermatol. 2004;45(1):47–50. doi:10.1111/j.1440-0960.2004.00030.x
   PubMedGoogle Scholar
• Shao F, Tan T, Tan Y, Sun Y, Wu X, Xu Q. Andrographolide alleviates imiquimod-induced psoriasis in mice via inducing autophagic proteolysis of MyD88. Biochem Pharmacol. 2016;115:94–103. doi:10.1016/j.bcp.2016.06.001
   PubMed Web of Science ®Google Scholar
• Cai Z, Zeng Y, Shi X, Zhang X, Zhu H, Wang W. Benvitimod inhibits MCM6-meditated proliferation of keratinocytes by regulating the JAK/STAT3 pathway. J Dermatol Sci. 2023;109(2):71–79. doi:10.1016/j.jdermsci.2023.01.010
   PubMed Web of Science ®Google Scholar
• Hollywood KA, Winder CL, Dunn WB, et al. Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Mol Biosyst. 2015;11(8):2198–2209. doi:10.1039/C4MB00739E
   PubMedGoogle Scholar
• Morar II, Tabăran FA, Mocan T, et al. Immunohistochemical study of psoriatic plaques and perilesional skin in psoriasis vulgaris patients: a pilot study. Exp Ther Med. 2019;18(2):888–894. doi:10.3892/etm.2019.7596
   PubMed Web of Science ®Google Scholar
• Pușcaș AD, Cătană A, Pușcaș C, et al. Psoriasis: association of interleukin-17 gene polymorphisms with severity and response to treatment. Exp Ther Med. 2019;18(2):875–880. doi:10.3892/etm.2019.7624
   PubMed Web of Science ®Google Scholar
• Bocheńska K, Smolińska E, Moskot M, Jakóbkiewicz-Banecka J, Gabig-Cimińska M. Models in the research process of psoriasis. Int J Mol Sci. 2017;18(12). doi:10.3390/ijms18122514
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi:10.1101/cshperspect.a016295
   PubMed Web of Science ®Google Scholar
• Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci. 2012;122(4):143–159. doi:10.1042/CS20110340
   PubMed Web of Science ®Google Scholar
• Horsten U, Schmitz-Van de Leur H, Müllberg J, Heinrich PC, Rose-John S. The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. FEBS Lett. 1995;360(1):43–46. doi:10.1016/0014-5793(95)00053-C
   PubMed Web of Science ®Google Scholar
• Moshapa FT, Riches-Suman K, Palmer TM. Therapeutic targeting of the proinflammatory IL-6-JAK/STAT signalling pathways responsible for vascular restenosis in type 2 diabetes mellitus. Cardiol Res Pract. 2019;2019:9846312. doi:10.1155/2019/9846312
   PubMed Web of Science ®Google Scholar
• Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1–15. doi:10.1016/j.cytogfr.2016.05.001
   PubMed Web of Science ®Google Scholar
• Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharma Bull. 2019;9(2):205–218. doi:10.15171/apb.2019.024
   PubMed Web of Science ®Google Scholar
• Song JY, Song L, Herrera AF, et al. Cyclin D1 expression in peripheral T-cell lymphomas. Modern Pathol. 2016;29(11):1306–1312. doi:10.1038/modpathol.2016.136
   PubMed Web of Science ®Google Scholar
• Kim SA, Ryu YW, Kwon JI, Choe MS, Jung JW, Cho JW. Differential expression of cyclin D1, Ki‑67, pRb, and p53 in psoriatic skin lesions and normal skin. Mol Med Rep. 2018;17(1):735–742. doi:10.3892/mmr.2017.8015
   PubMed Web of Science ®Google Scholar